Hansa Biopharma announced that Christian Kjellman, Chief Scientific Officer and Chief Operating Officer, has decided to leave the company in 2024. Effective immediately. Christian has been an important part of Hansa Biopharma since 2008 helping advance the Company's research and development projects through several critical milestones including regulatory approval of first drug candidate.

Additionally, in 2020 Christian assumed a dual leadership role ensuring tight integration and connectivity between the R&D and Commercial Operations functions during the early launch phase of the Company's first commercial product.